Special Issue "Potential Diagnostic and Therapeutic Roles of Extracellular Vesicles (EVs) in Tumor Progression"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 30 November 2023 | Viewed by 280

Special Issue Editors

Department of Chemical Pathology, Faculty of Health Sciences, School of Pathology, University of the Free State, Bloemfontein, South Africa
Interests: Drug discovery and delivery; nanotheranostics; extracellular vesicles; clinical biochemistry; chemical pathology
Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, Johannesburg 2028, South Africa
Interests: nanomedicine; biomaterials; photodynamic therapy; targeted drug delivery; photobiomodulation; wound healing

Special Issue Information

Dear Colleagues,

Relative oxygen stress is caused by imbalanced ROS generation and neutralization processes. Under these conditions, both internal and external forces stimulate cells. Oxidative stress causes cellular damage when it spirals out of control in the oxidation reduction system. In recent studies, it has been demonstrated that cellular stress increases extracellular vesicle (EV) release. EVs have a number of subpopulations, but three main types can be differentiated: exosomes, microvesicles, and apoptotic bodies. There has been an increase in research focusing on their relationship to cancer in recent years. EVs have a molecular signature that dynamically controls cancer. Tumor-derived EVs are the primary cause of cancer growth.

Tumor-derived EVs play a significant role in the formation of cancer stem cells and the development of treatment resistance and malignancy. EVs associated with specific molecular identities affect liquid biopic regions. Blood, plasma, urine, saliva, cerebrospinal fluid (CSF), and milk are just some of the biological fluids from which EVs can be separated. These prenatal cell sources can be used to determine the present state of the cells' pathogenic or healthy hallmark chemicals. Among cancer-specific indicators, EV molecular cargos have the greatest diagnostic and prognostic importance. Exosomes and nanoplatform-based sensors are next-generation diagnostic tools that can help us detect cancer at its earliest stages. EVs are currently at the core of a new direction in cancer therapy research. A number of therapeutic modalities, including immunotherapy based on exosomes, immune-cell-derived exosomes, and stem-cell-derived exosomes, have demonstrated favorable outcomes in clinical studies. The use of EVs for diagnostic and therapeutic purposes has not yet been fully explored.

We are interested in examining the critical role that exosomes play in controlling oxidative stress, cancer, and disorders associated with these conditions, as well as their potential therapeutic targets. We are interested in manuscripts that discuss the molecular causes of oxidative stress in cancer. We also encourage original research and review papers on the following topics (but not limited):

  • Oxidative stress and extracellular vesicles in cancer;
  • Extracellular vesicles and tumor progression: induction and inhibition;
  • Identifying and purifying cancer-derived extracellular vesicles;
  • Cancer prognosis and diagnosis using extracellular vesicles markers;
  • Genomics, proteomics, and metabolomics analysis of cancer-derived extracellular vesicles;
  • Extracellular vesicles signaling in cancer cells;
  • Extracellular vesicles in immune regulation;
  • Extracellular vesicles as tumor vaccines;
  • Drug delivery applications of extracellular vesicles;
  • Therapeutic applications of extracellular vesicles in cancer.

Dr. Krishnan Anand
Dr. Sathish Sundar Dhilip Kumar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • extracellular vesicles (EVs)
  • exosomes
  • circulating biomarkers
  • cancer therapeutics
  • tumor microenvironment
  • metastasis

Published Papers

This special issue is now open for submission.
Back to TopTop